Epigenetics and immunotherapy

The current state of play

Jennifer Dunn, Sudha Rao

Research output: Contribution to journalArticle

61 Citations (Scopus)
3 Downloads (Pure)

Abstract

Cancer cells employ a number of mechanisms to escape immunosurveillance and facilitate tumour progression. The recent explosion of interest in immunotherapy, especially immune checkpoint blockade, is a result of discoveries about the fundamental ligand-receptor interactions that occur between immune and cancer cells within the tumour microenvironment. Distinct ligands expressed by cancer cells engage with cell surface receptors on immune cells, triggering inhibitory pathways (such as PD-1/PD-L1) that render immune cells immunologically tolerant. Importantly, recent studies on the role of epigenetics in immune evasion have exposed a key role for epigenetic modulators in augmenting the tumour microenvironment and restoring immune recognition and immunogenicity. Epigenetic drugs such as DNA methyltransferase and histone deacetylase inhibitors can reverse immune suppression via several mechanisms such as enhancing expression of tumour-associated antigens, components of the antigen processing and presenting machinery pathways, immune checkpoint inhibitors, chemokines, and other immune-related genes. These discoveries have established a highly promising basis for studies using combined epigenetic and immunotherapeutic agents as anti-cancer therapies. In this review, we discuss the exciting role of epigenetic immunomodulation in tumour immune escape, emphasising its significance in priming and sensitising the host immune system to immunotherapies through mechanisms such as the activation of the viral defence pathway. With this background in mind, we highlight the promise of combined epigenetic therapy and immunotherapy, focusing on immune checkpoint blockade, to improve outcomes for patients with many different cancer types.

Original languageEnglish
Pages (from-to)227-239
Number of pages13
JournalMolecular Immunology
Volume87
DOIs
Publication statusPublished - 1 Jul 2017

Fingerprint

Epigenomics
Immunotherapy
Neoplasms
Tumor Microenvironment
Tumor Escape
Ligands
Immune Evasion
Immunologic Monitoring
Virus Activation
Histone Deacetylase Inhibitors
Immunomodulation
Explosions
Antigen Presentation
Methyltransferases
Cell Surface Receptors
Neoplasm Antigens
Chemokines
Immune System
DNA
Therapeutics

Cite this

@article{16290b330c8b437c897a4f88d452f2e7,
title = "Epigenetics and immunotherapy: The current state of play",
abstract = "Cancer cells employ a number of mechanisms to escape immunosurveillance and facilitate tumour progression. The recent explosion of interest in immunotherapy, especially immune checkpoint blockade, is a result of discoveries about the fundamental ligand-receptor interactions that occur between immune and cancer cells within the tumour microenvironment. Distinct ligands expressed by cancer cells engage with cell surface receptors on immune cells, triggering inhibitory pathways (such as PD-1/PD-L1) that render immune cells immunologically tolerant. Importantly, recent studies on the role of epigenetics in immune evasion have exposed a key role for epigenetic modulators in augmenting the tumour microenvironment and restoring immune recognition and immunogenicity. Epigenetic drugs such as DNA methyltransferase and histone deacetylase inhibitors can reverse immune suppression via several mechanisms such as enhancing expression of tumour-associated antigens, components of the antigen processing and presenting machinery pathways, immune checkpoint inhibitors, chemokines, and other immune-related genes. These discoveries have established a highly promising basis for studies using combined epigenetic and immunotherapeutic agents as anti-cancer therapies. In this review, we discuss the exciting role of epigenetic immunomodulation in tumour immune escape, emphasising its significance in priming and sensitising the host immune system to immunotherapies through mechanisms such as the activation of the viral defence pathway. With this background in mind, we highlight the promise of combined epigenetic therapy and immunotherapy, focusing on immune checkpoint blockade, to improve outcomes for patients with many different cancer types.",
keywords = "Combination therapy, DNA methyltransferase inhibitors, Epigenetics, Histone deacetylase inhibitors, Immune checkpoint blockade, Immunotherapy, Tumor Escape/genetics, Immunotherapy/methods, Humans, Neoplasms/genetics, Animals, Tumor Microenvironment/genetics, Epigenesis, Genetic/genetics",
author = "Jennifer Dunn and Sudha Rao",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.molimm.2017.04.012",
language = "English",
volume = "87",
pages = "227--239",
journal = "Immunochemistry",
issn = "0161-5890",
publisher = "Elsevier Limited",

}

Epigenetics and immunotherapy : The current state of play. / Dunn, Jennifer; Rao, Sudha.

In: Molecular Immunology, Vol. 87, 01.07.2017, p. 227-239.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Epigenetics and immunotherapy

T2 - The current state of play

AU - Dunn, Jennifer

AU - Rao, Sudha

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Cancer cells employ a number of mechanisms to escape immunosurveillance and facilitate tumour progression. The recent explosion of interest in immunotherapy, especially immune checkpoint blockade, is a result of discoveries about the fundamental ligand-receptor interactions that occur between immune and cancer cells within the tumour microenvironment. Distinct ligands expressed by cancer cells engage with cell surface receptors on immune cells, triggering inhibitory pathways (such as PD-1/PD-L1) that render immune cells immunologically tolerant. Importantly, recent studies on the role of epigenetics in immune evasion have exposed a key role for epigenetic modulators in augmenting the tumour microenvironment and restoring immune recognition and immunogenicity. Epigenetic drugs such as DNA methyltransferase and histone deacetylase inhibitors can reverse immune suppression via several mechanisms such as enhancing expression of tumour-associated antigens, components of the antigen processing and presenting machinery pathways, immune checkpoint inhibitors, chemokines, and other immune-related genes. These discoveries have established a highly promising basis for studies using combined epigenetic and immunotherapeutic agents as anti-cancer therapies. In this review, we discuss the exciting role of epigenetic immunomodulation in tumour immune escape, emphasising its significance in priming and sensitising the host immune system to immunotherapies through mechanisms such as the activation of the viral defence pathway. With this background in mind, we highlight the promise of combined epigenetic therapy and immunotherapy, focusing on immune checkpoint blockade, to improve outcomes for patients with many different cancer types.

AB - Cancer cells employ a number of mechanisms to escape immunosurveillance and facilitate tumour progression. The recent explosion of interest in immunotherapy, especially immune checkpoint blockade, is a result of discoveries about the fundamental ligand-receptor interactions that occur between immune and cancer cells within the tumour microenvironment. Distinct ligands expressed by cancer cells engage with cell surface receptors on immune cells, triggering inhibitory pathways (such as PD-1/PD-L1) that render immune cells immunologically tolerant. Importantly, recent studies on the role of epigenetics in immune evasion have exposed a key role for epigenetic modulators in augmenting the tumour microenvironment and restoring immune recognition and immunogenicity. Epigenetic drugs such as DNA methyltransferase and histone deacetylase inhibitors can reverse immune suppression via several mechanisms such as enhancing expression of tumour-associated antigens, components of the antigen processing and presenting machinery pathways, immune checkpoint inhibitors, chemokines, and other immune-related genes. These discoveries have established a highly promising basis for studies using combined epigenetic and immunotherapeutic agents as anti-cancer therapies. In this review, we discuss the exciting role of epigenetic immunomodulation in tumour immune escape, emphasising its significance in priming and sensitising the host immune system to immunotherapies through mechanisms such as the activation of the viral defence pathway. With this background in mind, we highlight the promise of combined epigenetic therapy and immunotherapy, focusing on immune checkpoint blockade, to improve outcomes for patients with many different cancer types.

KW - Combination therapy

KW - DNA methyltransferase inhibitors

KW - Epigenetics

KW - Histone deacetylase inhibitors

KW - Immune checkpoint blockade

KW - Immunotherapy

KW - Tumor Escape/genetics

KW - Immunotherapy/methods

KW - Humans

KW - Neoplasms/genetics

KW - Animals

KW - Tumor Microenvironment/genetics

KW - Epigenesis, Genetic/genetics

UR - http://www.scopus.com/inward/record.url?scp=85019207258&partnerID=8YFLogxK

U2 - 10.1016/j.molimm.2017.04.012

DO - 10.1016/j.molimm.2017.04.012

M3 - Article

VL - 87

SP - 227

EP - 239

JO - Immunochemistry

JF - Immunochemistry

SN - 0161-5890

ER -